Profile data is unavailable for this security.
About the company
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
- Revenue in USD (TTM)0.00
- Net income in USD-427.49m
- Incorporated2013
- Employees390.00
- LocationDenali Therapeutics Inc161 Oyster Point BlvdSOUTH SAN FRANCISCO 94080-1910United StatesUSA
- Phone+1 (650) 866-8548
- Fax+1 (302) 655-5049
- Websitehttps://www.denalitherapeutics.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vera Therapeutics Inc | 0.00 | -134.38m | 2.98bn | 82.00 | -- | 8.95 | -- | -- | -2.60 | -2.60 | 0.00 | 5.25 | 0.00 | -- | -- | 0.00 | -49.39 | -- | -54.50 | -- | -- | -- | -- | -- | -- | -- | 0.1487 | -- | -- | -- | -7.79 | -- | -- | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -213.39m | 3.02bn | 251.00 | -- | 3.78 | -- | -- | -2.81 | -2.81 | 0.00 | 10.53 | 0.00 | -- | -- | 0.00 | -28.32 | -20.71 | -29.38 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Veracyte Inc | 425.33m | -9.27m | 3.02bn | 815.00 | -- | 2.57 | 211.42 | 7.10 | -0.1445 | -0.1445 | 5.61 | 15.18 | 0.3545 | 7.40 | 9.66 | 521,878.50 | -0.7723 | -6.33 | -0.8157 | -6.69 | 68.45 | 67.10 | -2.18 | -20.99 | 4.79 | -- | 0.00009 | -- | 21.76 | 31.45 | -103.51 | -- | 39.67 | -- |
| Dyne Therapeutics Inc | 0.00 | -294.51m | 3.03bn | 173.00 | -- | 4.29 | -- | -- | -3.56 | -3.56 | 0.00 | 6.93 | 0.00 | -- | -- | 0.00 | -60.47 | -52.81 | -65.37 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Edgewise Therapeutics Inc | 0.00 | -124.29m | 3.03bn | 108.00 | -- | 6.18 | -- | -- | -1.49 | -1.49 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -30.22 | -- | -31.57 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
| Agios Pharmaceuticals Inc | 32.87m | 727.43m | 3.17bn | 383.00 | 4.52 | 1.95 | 4.32 | 96.36 | 12.28 | 11.37 | 0.5778 | 28.53 | 0.0235 | 0.1598 | 15.31 | 85,825.06 | 51.98 | -29.54 | 55.50 | -31.88 | 89.38 | -- | 2,212.98 | -3,826.10 | 8.77 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
| MoonLake Immunotherapeutics | 0.00 | -80.77m | 3.31bn | 50.00 | -- | 6.70 | -- | -- | -1.29 | -1.29 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -16.25 | -- | -18.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Denali Therapeutics Inc | 0.00 | -427.49m | 3.49bn | 390.00 | -- | 2.64 | -- | -- | -2.76 | -2.76 | 0.00 | 9.17 | 0.00 | -- | -- | 0.00 | -31.77 | -14.98 | -33.76 | -17.71 | -- | -- | -- | -104.50 | -- | -- | 0.0043 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Immunitybio Inc | 7.33m | -587.79m | 3.51bn | 672.00 | -- | -- | -- | 478.32 | -0.867 | -0.867 | 0.0108 | -1.07 | 0.0184 | -- | 1.53 | 11,675.16 | -147.53 | -112.76 | -182.67 | -316.07 | -- | -- | -8,018.00 | -37,700.74 | 2.64 | -2.19 | 4.22 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Rhythm Pharmaceuticals Inc | 112.53m | -261.57m | 3.63bn | 226.00 | -- | 323.37 | -- | 32.24 | -4.31 | -4.31 | 1.86 | 2.49 | 0.3136 | 1.18 | 6.65 | 497,920.30 | -72.15 | -47.21 | -90.85 | -52.84 | 88.61 | -- | -230.11 | -681.38 | 3.34 | -- | 0.417 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Alvotech SA | 393.92m | -441.45m | 3.75bn | 999.00 | -- | -- | -- | 9.52 | -1.90 | -1.90 | 1.56 | -1.29 | 0.3595 | 1.56 | 4.24 | 394,313.30 | -40.28 | -- | -47.87 | -- | 59.03 | -- | -112.07 | -- | 1.92 | -0.0519 | 1.41 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Immunovant Inc | 0.00 | -323.01m | 3.90bn | 207.00 | -- | 8.66 | -- | -- | -2.21 | -2.21 | 0.00 | 3.06 | 0.00 | -- | -- | 0.00 | -79.97 | -- | -92.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 30 Sep 2024 | 13.35m | 9.32% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 10.87m | 7.59% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 10.62m | 7.42% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 9.92m | 6.93% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 7.91m | 5.52% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 7.81m | 5.46% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 30 Sep 2024 | 5.36m | 3.74% |
| Crestline Management LPas of 30 Sep 2024 | 4.46m | 3.12% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 4.25m | 2.97% |
| Baker Bros. Advisors LPas of 30 Sep 2024 | 3.73m | 2.61% |
